Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatm...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.731895/full |
| _version_ | 1818360793074237440 |
|---|---|
| author | Gang Shen Lei Shi Xin Tian Depei Huang Hao Chen Chan Gao Xudong Shen Hushan Zhang |
| author_facet | Gang Shen Lei Shi Xin Tian Depei Huang Hao Chen Chan Gao Xudong Shen Hushan Zhang |
| author_sort | Gang Shen |
| collection | DOAJ |
| description | Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatment option. Herein, we report a patient with metastatic NSCLC who benefited from almonertinib after developing resistance to osimertinib. |
| first_indexed | 2024-12-13T21:06:26Z |
| format | Article |
| id | doaj.art-ff0e5250c91a42b3b319ac7f8139c7ee |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-13T21:06:26Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-ff0e5250c91a42b3b319ac7f8139c7ee2022-12-21T23:31:28ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-12-011210.3389/fphar.2021.731895731895Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q MutationGang Shen0Lei Shi1Xin Tian2Depei Huang3Hao Chen4Chan Gao5Xudong Shen6Hushan Zhang7Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaDepartment of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, ChinaThe Medical Department, 3D Medicines Inc., Shanghai, ChinaThe Bioinformatics Department, 3D Medicines Inc., Shanghai, ChinaThe Medical Department, 3D Medicines Inc., Shanghai, ChinaThe Medical Department, 3D Medicines Inc., Shanghai, ChinaThe Medical Department, 3D Medicines Inc., Shanghai, ChinaOsimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatment option. Herein, we report a patient with metastatic NSCLC who benefited from almonertinib after developing resistance to osimertinib.https://www.frontiersin.org/articles/10.3389/fphar.2021.731895/fullNSCLC-lung adenocarcinoma-EGFR-ALK-BRAF-KRAS-RET-MET-PD-L1-ROS1.EGFRTKI-tyrosine kinase inhibitoralmonertinibL718Q |
| spellingShingle | Gang Shen Lei Shi Xin Tian Depei Huang Hao Chen Chan Gao Xudong Shen Hushan Zhang Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation Frontiers in Pharmacology NSCLC-lung adenocarcinoma-EGFR-ALK-BRAF-KRAS-RET-MET-PD-L1-ROS1. EGFR TKI-tyrosine kinase inhibitor almonertinib L718Q |
| title | Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation |
| title_full | Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation |
| title_fullStr | Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation |
| title_full_unstemmed | Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation |
| title_short | Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation |
| title_sort | case report response to almonertinib in a patient with metastatic nsclc resistant to osimertinib due to acquired egfr l718q mutation |
| topic | NSCLC-lung adenocarcinoma-EGFR-ALK-BRAF-KRAS-RET-MET-PD-L1-ROS1. EGFR TKI-tyrosine kinase inhibitor almonertinib L718Q |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.731895/full |
| work_keys_str_mv | AT gangshen casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation AT leishi casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation AT xintian casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation AT depeihuang casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation AT haochen casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation AT changao casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation AT xudongshen casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation AT hushanzhang casereportresponsetoalmonertinibinapatientwithmetastaticnsclcresistanttoosimertinibduetoacquiredegfrl718qmutation |